Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1794-1800

  Park, Jaeyong ^a,c   Lee, Won Kee ^a   Jung, Duk Ku ^a   Choi, Jin Eun ^a   Park, Tae In ^a   Lee, Eung Bae ^a   Cho, Sukki ^a   Park, Ji Young ^a   Cha, Sung Ick ^a   Kim, Chang Ho ^a   Kam, Sin ^a   Jung, Tae Hoon ^a   Jheon, Sanghoon ^b  

^a Kyungpook National University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMORPHIC LOCUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; ANTIGENS, CD95; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FAS LIGAND PROTEIN; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 63549094741     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1770     Document Type: Article

References (36)

1. Thompson CB. Apoptosis is the pathogenesis and treatment of disease. Science 1995;267:1456-62.
2. Raff M. Cell suicide for beginners. Nature 1998;396: 119-22.
3. Shivapurkar N, Reddy J, Chaudhary PM, et al. Apoptosis and lung cancer: a review. J Cell Biochem 2003;88:885-98.
4. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 2004;9:691 -704.
5. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
6. Nagara S, Goldstein P. The Fas death receptor. Science 1995;267:1449-56.
7. Xerri L, Devilard E, Hassoun J, et al. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 1997;50:87-91.
8. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
9. Oehm A, Behrmann I, Falk W, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992;267: 10709-15.
10. SudaT,TakahashiT, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75: 1169-78.
11. Niehans GA, BrunnerT, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57: 1007-12.
12. Nambu Y, Hughes SJ, Rehemtulla A, et al. Lack of cell surface FAS/APO-1 expression in pulmonary adenocarcinoma. J Clin Invest1998;101:1102 -10.
13. Koomagi R, Volm M. Expression of FAS (CD95/ APO-1) and FAS ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999;84: 239-43.
14. Viard-Leveugle I,Veyrenc S, French LE, et al. Frequent loss of Fas expression and function in human lung tumors with overexpression of FasL in small cell lung carcinoma. J Pathol 2003;201:268-77.
15. Griffith TS, BrunnerT, Fletcher SM, et al. Fas-ligand induced apoptosis as a mechanism of immune privilege. Science1995;270:1189 -92.
16. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/CD95) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 1996;2:1361 -6.
17. Muschen M,Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000; 78:312-25.
18. Reichman E.Thebiological roleof theFas/FasL system during tumor formation and progression. Semin Cancer Biol 2002;12:309 -15.
19. Uramoto H, Osaki T, Inoue M, et al. Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 1999;35:1462-5.
20. Volm M, Koomagi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. BrJ Cancer 2000;82:1747 -54.
21. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-82.
22. Sibley K, Rollinson S, Allan JM, et al. A functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327 -30.
23. Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancer-binding protein β element in the FasL gene promoter alters Fas ligand expression: a candi date background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170: 132-8.
24. Sun T, Miao X, Zhang X, et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous cell carcinoma. J Natl Cancer Inst 2004; 96:1030-6.
25. Wang LE, Cheng L, Spitz MR, et al. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 2003;42: 1-8.
26. Zhang X, Miao X, SunT, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005; 42:479 -84.
27. Zhang B, Sun T, Xue L, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007;28:1067-73.
28. Brambilla E, Travis WD, ColbyTV, et al. The new World Health Organization classification of lung tumors. Eur RespirJ 2001;18:1059 -68.
29. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest1997;111:1710-7.
30. Park SH, Choi JE, Kim EJ, et al. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 2006;54:303-8.
31. δδCt method. Methods 2001;25:402-8.
32. Stephens M, Smith MJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
33. Bel HJB,MahfouthW,BouaouinaN,etal. Apolymor-phismin FAS gene promoter associated with increased risk nasopharyngeal carcinoma and correlated with anti nuclear autoantibodies induction. CancerLett2006; 233:21 -7.
34. Joseph B, Lewensohn R, Zhivotovsky B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann N Y Acad Sci 2000;926: 204-16.
35. Dotor E, Cuatrecases M, Martinez-Iniesta M, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006;24:1603 -11.
36. Kim JG, Sohn SK, Chae YS, et al.Vascular end of thelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 2007;18:1030-6.